Cargando…

Pharmacokinetics of enoxaparin in COVID-19 critically ill patients

BACKGROUND: In intensive-care unit (ICU) patients, pathophysiological changes may affect the pharmacokinetics of enoxaparin and result in underdosing. OBJECTIVES: To develop a pharmacokinetic model of enoxaparin to predict the time-exposure profiles of various thromboprophylactic regimens in COVID-1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zufferey, Paul Jacques, Dupont, Annabelle, Lanoiselée, Julien, Bauters, Anne, Poissy, Julien, Goutay, Julien, Jean, Laurent, Caplan, Morgan, Levy, Lionel, Susen, Sophie, Delavenne, Xavier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8294601/ https://www.ncbi.nlm.nih.gov/pubmed/34311154 http://dx.doi.org/10.1016/j.thromres.2021.07.010

Ejemplares similares

Endotheliopathy Is Induced by Plasma From Critically Ill Patients and Associated With Organ Failure in Severe COVID-19
por: Rauch, Antoine, et al.
Publicado: (2020)

Plasma Markers of Neutrophil Extracellular Trap Are Linked to Survival but Not to Pulmonary Embolism in COVID-19-Related ARDS Patients
por: Prével, Renaud, et al.
Publicado: (2022)

Population pharmacokinetic model of cefazolin in total hip arthroplasty
por: Lanoiselée, J., et al.
Publicado: (2021)

Development of a Decision Support Tool for Anticoagulation in Critically Ill Patients Admitted for SARS-CoV-2 Infection: The CALT Protocol
por: Dubar, Victoria, et al.
Publicado: (2023)

Clinico-Biological Features and Clonal Hematopoiesis in Patients with Severe COVID-19
por: Duployez, Nicolas, et al.
Publicado: (2020)

Altered microRNA expression in severe COVID‐19: Potential prognostic and pathophysiological role
por: Garnier, Nathalie, et al.
Publicado: (2022)

Derivation and Validation of a Predictive Score for Respiratory Failure Worsening Leading to Secondary Intubation in COVID-19: The CERES Score
por: Gaudet, Alexandre, et al.
Publicado: (2022)

Spatial and Temporal Virus Load Dynamics of SARS-CoV-2: A Single-Center Cohort Study
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2021)

Hyperbaric hyperoxemia as a risk factor for ventilator-acquired pneumonia?
por: Caplan, Morgan, et al.
Publicado: (2021)

Impact of High-Dose Prophylactic Anticoagulation in Critically Ill Patients With COVID-19 Pneumonia
por: Tacquard, Charles, et al.
Publicado: (2021)

Time to consider histologic pattern of lung injury to treat critically ill patients with COVID-19 infection
por: Copin, Marie-Christine, et al.
Publicado: (2020)

Anti-activated factor × response to enoxaparin in critically ill patients
por: Einav, S, et al.
Publicado: (2009)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

MicroARN en tant que biomarqueurs de la COVID-19 grave
por: Menasria, S., et al.
Publicado: (2021)

De-escalation of antifungal treatment in critically ill patients with suspected invasive Candida infection: incidence, associated factors, and safety
por: Jaffal, Karim, et al.
Publicado: (2018)

Adverse events during intrahospital transport of critically ill patients: incidence and risk factors
por: Parmentier-Decrucq, Erika, et al.
Publicado: (2013)

Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill?
por: Priglinger, U, et al.
Publicado: (2002)

Efficacy and safety of enoxaparin as deep vein thrombosis prophylaxis in critically ill patients
por: Al-Hubail, R, et al.
Publicado: (2012)

Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
por: Barbier, François, et al.
Publicado: (2023)

Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile
por: Clemens, Andreas, et al.
Publicado: (2012)

Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients
por: Lage, S, et al.
Publicado: (2006)

Measurement site of inferior vena cava diameter affects the accuracy with which fluid responsiveness can be predicted in spontaneously breathing patients: a post hoc analysis of two prospective cohorts
por: Caplan, Morgan, et al.
Publicado: (2020)

Enoxaparin-Induced DRESS Syndrome
por: Ronceray, Sophie, et al.
Publicado: (2012)

Assessment of Metabolic Dysfunction in Sepsis in a Retrospective Single-Centre Cohort
por: Goutay, Julien, et al.
Publicado: (2021)

The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin
por: Prandoni, Paolo, et al.
Publicado: (2020)

Assessment of plasma endocan for the prediction of mortality in COVID-19 patients undergoing veno-venous ECMO: A pilot study
por: Levy, C., et al.
Publicado: (2023)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Circulating Monocyte Subsets and Transcatheter Aortic Valve Replacement
por: Lassalle, Fanny, et al.
Publicado: (2022)

Severe Intraabdominal Hypertension in Critically Ill COVID-19 Patients With Acute Kidney Injury
por: Dupont, Vincent, et al.
Publicado: (2021)

Severe SARS‐CoV‐2 patients develop a higher specific T‐cell response
por: Demaret, Julie, et al.
Publicado: (2020)

What applications for plasma endocan measurement in intensive care? A clarification
por: Dubar, Victoria, et al.
Publicado: (2023)

Colon cancer surgery in von Willebrand disease type 3 setting triggering vascular abnormalities on bowel anastomosis
por: Rauch, Antoine, et al.
Publicado: (2023)

Use of Real‐World Data and Physiologically‐Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Efficacy and Safety of Two Different Enoxaparin Doses for Thromboprophylaxis in Non-critically Ill Patients: A Randomized Controlled Trial
por: Alavi-Darazam, Ilad, et al.
Publicado: (2022)

Utilizing enoxaparin in the management of STEMI
por: Rubboli, Andrea, et al.
Publicado: (2007)

Enoxaparin-Induced Skin Necrosis
por: Coelho, James, et al.
Publicado: (2016)

Enoxaparin-Induced Liver Injury
por: Mehershahi, Shehriyar, et al.
Publicado: (2020)

Double-Blind Randomized Clinical Trial to Examine the Pharmacokinetic and Clinical Impacts of Fixed Dose versus Weight-based Enoxaparin Prophylaxis: A Methodologic Description of the FIxed or Variable Enoxaparin (FIVE) Trial
por: Pannucci, Christopher J., et al.
Publicado: (2019)

Effects of intermittent hemodialysis on plasmatic levels of endocan
por: Hureau, Maxence, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8lcgkmue89mu9dfu3vf5724p5e